Roche Holding | ROG - Des Atouts





Des Atouts Changement Date
AbbVie USD 136.46B 2.5B 2026-03
Alcon AG USD 31.62B 64M 2026-03
Almirall EUR 2.34B 29.21M 2025-12
Amgen USD 92.5B 1.92B 2026-03
AstraZeneca USD 114.02B 59M 2026-03
Bayer EUR 107.94B 3.4B 2026-03
Biogen USD 29.48B 43.6M 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Eli Lilly USD 116.58B 4.1B 2026-03
Fresenius EUR 41.4B 1.07B 2025-12
Fresenius Medical Care EUR 31.47B 465.26M 2026-03
Genmab DKK 12.87B 5.85B 2025-12
Gilead Sciences USD 56.28B 2.74B 2026-03
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
GRIFOLS EUR 20.08B 366M 2026-03
Hikma Pharmaceutical USD 5.67B 117M 2025-12
Lakefront Biotherapeutics EUR 3.37B 34.09M 2026-03
Lonza CHF 18.97B 164M 2025-12
Merck EUR 53.07B 1.54B 2026-03
Merck USD 128.68B 8.18B 2026-03
Novartis USD 118.53B 7.58B 2026-03
Orion EUR 1.87B 205.5M 2026-06
Pfizer USD 207.62B 542M 2026-03
Philips EUR 27.27B 322M 2026-03
Recordati EUR 5.33B 82.27M 2026-03
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Roche Holding CHF 100.7B 5.94B 2025-12
Sanofi EUR 128.02B 1.22B 2026-03
UCB EUR 18.16B 971M 2025-12